In human studies, serum leptin levels were found to be increased prior to onset of clinical symptoms in relapsing-remitting MS, indicating that leptin may both contribute to the pathogenesis of MS and be a useful marker of disease (99, 100). This evidence concerns the gene LEP and myeloid sarcoma.